Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 14/20 | 1.00 |
| ▸ | CA2 | P00918 | 14/20 | 1.00 |
| ▸ | CA9 | Q16790 | 8/20 | 1.00 |
| ▸ | CA12 | O43570 | 6/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.76 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.71 |
| ▸ | CA4 | P22748 | 2/20 | 0.71 |
| ▸ | CA7 | P43166 | 3/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2472778 | 0.89 | CA1 (1.00) | CA1CA2CA9CA12MEN1 | |
| SCHEMBL15906737 | 0.88 | CA1 (0.97) | CA1CA2CA9CA12MEN1 | |
| SCHEMBL15906718 | 0.88 | CA1 (0.97) | CA1CA2CA9CA12MEN1 | |
| SCHEMBL2476370 | 0.88 | CA1 (0.97) | CA1CA2CA9CA12MEN1 | |
| SCHEMBL11476737 | 0.88 | CA1 (0.97) | CA1CA2CA9CA12MEN1 | |
| SCHEMBL17510035 | 0.87 | CA1 (0.77) | CA1CA2CA9CA12MEN1 | |
| SCHEMBL13263684 | 0.86 | CA1 (1.00) | CA1CA2CA9CA12MEN1 | |
| SCHEMBL22947041 | 0.86 | CA1 (0.75) | CA1CA2CA9CA12MEN1 | |
| SCHEMBL12994196 | 0.85 | CA1 (0.73) | CA1CA2CA9CA12MEN1 | |
| Sulfasuccinamide SCHEMBL20118963 | 0.83 | CA1 (1.00) | CA1CA2CA9CA12MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1392643-B1 | TRISUBSTITUTED-N- (1S)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENYL] BENZAMIDES WHICH INHIBIT P2X3 AND P2X2/3 CONTAINING RECEPTORS | ABBOTT LAB (US) | 2005-09-14 | — | — | EP | disclosed |
| US-6831193-B2 | Treating pain, urinary incontinence and bladder overactivity; P2X receptors are cation-permeable ion channels | ABBOTT LABORATORIES | 2004-12-14 | — | — | US | disclosed |
| EP-1392643-A2 | TRISUBSTITUTED-N- (1S)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENYL] BENZAMIDES WHICH INHIBIT P2X3 AND P2X2/3 CONTAINING RECEPTORS | Abbott Laboratories (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20030083359-A1 | Trisubstituted-N-[(1S)-1,2,3,4-terrahydro-1-naphthalenyl]benzamides which inhibit P2X2/3 containing receptors | ABBVIE INC. | 2003-05-01 | — | — | US | disclosed |
| WO-2002094767-A2 | TRISUBSTITUTED-N-[(1S)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENYL] BENZAMIDES WHICH INHIBIT P2X3 AND P2X2/3 CONTAINING RECEPTORS | ABBOTT LABORATORIES (US) | 2002-11-28 | — | — | WO | disclosed |
| EP-0638075-B1 | THIAZOLE OR IMIDAZOLE DERIVATIVES AS MAILLARD REACTION INHIBITORS | OTSUKA PHARMA CO LTD (JP) | 2002-01-16 | — | — | EP | disclosed |
| WO-1998043649-A2 | AGE PRODUCTION INHIBITORY COMPOSITION COMPRISING A MAILLARD REACTION INHIBITOR AND VITAMIN B¿6? | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1998-10-08 | — | — | WO | disclosed |
| US-5677322-A | THERAPY FOR AGING, DIABETES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083359-A1 | Trisubstituted-N-[(1S)-1,2,3,4-terrahydro-1-naphthalenyl]benzamides which inhibit P2X2/3 containing receptors | P2RX3, P2RX1, P2RX2 | CA1 2300/4885CA2 380/4885CA9 1628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.